Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077052 | 0.79 | TACR1 (0.46) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL1475971 | 0.70 | HTR2A (0.58) | TACR1 | |
| SCHEMBL2074166 | 0.69 | HTR2A (0.54) | TACR1ACHEGABRA1GABRA2 | |
| SCHEMBL4635032 | 0.68 | ACHE (0.52) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL4635033 | 0.68 | ACHE (0.52) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL5808405 | 0.68 | TACR1 (0.46) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL6043648 | 0.66 | ACHE (0.42) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL6043641 | 0.66 | ACHE (0.42) | TACR1DRD4DRD2ACHEBCHE | |
| SCHEMBL5012169 | 0.64 | ACHE (0.51) | TACR1ACHEBCHEBACE1GRIN1 | |
| SCHEMBL6943959 | 0.64 | TACR1 (0.62) | TACR1ACHEBCHEBACE1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | TACR1 259/4885DRD4 112/4885DRD2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.